Prolonged dual antiplatelet therapy in stable coronary disease: comparative observational study of benefits and harms in unselected versus trial populations - Wikidata - awgldk - TriplyDB

Prolonged dual antiplatelet therapy in stable coronary disease: comparative observational study of benefits and harms in unselected versus trial populations

Prolonged dual antiplatelet therapy in stable coronary disease: comparative observational study of benefits and harms in unselected versus trial populations

http://www.wikidata.org/entity/Q28600880

about

Personalising the decision for prolonged dual antiplatelet therapy: development, validation and potential impact of prognostic models for cardiovascular events and bleeding in myocardial infarction survivors.β-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction.Methods for enhancing the reproducibility of biomedical research findings using electronic health records.Outcomes in patients after myocardial infarction similar to those of the PEGASUS-TIMI 54 trial: A cohort study in the French national claims database.

P2860

Q33589630-D3D7C491-7E65-4177-9104-3009B50D27E9 Q33758547-7F940461-6F68-4B98-8FF3-16685EC35146 Q40039830-AF3D576F-F717-489F-AEBA-0887EE8B5B2A Q40272818-927F1909-0710-4C7C-9F2C-66D67DB6E6CC

P2860

Prolonged dual antiplatelet therapy in stable coronary disease: comparative observational study of benefits and harms in unselected versus trial populations

http://www.wikidata.org/entity/Q28600880

description

2016 nî lūn-bûn

@nan

2016 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Prolonged dual antiplatelet th ...... ected versus trial populations

@ast

Prolonged dual antiplatelet th ...... ected versus trial populations

@en

Prolonged dual antiplatelet th ...... ected versus trial populations

@nl

type

label

Prolonged dual antiplatelet th ...... ected versus trial populations

@ast

Prolonged dual antiplatelet th ...... ected versus trial populations

@en

Prolonged dual antiplatelet th ...... ected versus trial populations

@nl

prefLabel

Prolonged dual antiplatelet th ...... ected versus trial populations

@ast

Prolonged dual antiplatelet th ...... ected versus trial populations

@en

Prolonged dual antiplatelet th ...... ected versus trial populations

@nl

P1433

Q28600880-B376334E-5208-42DD-905B-46C2579DCD10

P1476

Q28600880-BC3601AF-FE1E-47ED-BE35-B977ABEF4FB6

P2093

Q28600880-005FDBFE-F393-4B45-8F92-409B7E5191EC

Q28600880-45DB78EF-9D61-4128-A8CB-6EC32298363D

Q28600880-56F55632-2C70-4628-9619-A628BC22B4AF

Q28600880-58A5205C-9B2E-46CA-BAC4-D332BEF6F11A

Q28600880-68EA846E-18F0-4883-A0DA-2D42C5BFD37C

Q28600880-91717CBD-5162-4499-9BD9-D4A9C0392ACD

Q28600880-E08982C5-890E-4C9E-AC7A-83B68EDE970A

Q28600880-E3C701F9-6389-4D65-8827-2446A956089C

P2860

Q28600880-037AB2D8-6637-4D9D-A676-FF895EFE9456

Q28600880-0828EB9B-FA9D-4E8F-8D4F-4A79E44E577B

Q28600880-0E262BDA-1D3A-45DB-B061-84134895F502

Q28600880-10E49104-870A-4FD1-A317-ACB72642F834

Q28600880-3360AB96-15F1-45D2-AD79-6C7208FBCB91

Q28600880-34B3D858-14CA-4B49-8B9B-0052DE04163F

Q28600880-37F007FC-47BE-4D7F-9650-48EB5B6D1E50

Q28600880-39E7CC6E-A41F-4CCD-AD01-A3C4EFF15D79

Q28600880-466090FB-1015-4F3C-9A38-0AE0CDFD5CAB

Q28600880-6292F53C-BF71-4B4F-BA51-8A07039C93D9

P304

Q28600880-710E04B4-253D-4DD5-9E64-4D7943FB158A

P31

Q28600880-A148565B-F905-4E67-8F74-F05CD6410334

P3181

Q28600880-E416C797-9F0D-48DB-B204-5771E0C26D46

P356

Q28600880-77344BF5-0601-495A-9FEB-38C639A04D3A

P407

Q28600880-F092A9CA-9849-4469-9DBE-7581948F45D8

P478

Q28600880-DC99B47E-0442-4BFF-96FC-CA53AD68CDE3

P50

Q28600880-0E202207-9533-4F50-87C4-CAB33EB30DFA

Q28600880-4C1E393A-709B-4262-B8EB-0E18C0260059

Q28600880-7BD96E71-E7DC-428F-B4BE-2CF523D0FA16

P5530

Q28600880-8E6B94BB-9C00-44CC-A1D8-78A1BB589ABD

P577

Q28600880-26AFA450-1BB0-4BDA-90F7-ED1B99B3F42A

P6179

Q28600880-5AD89273-BAFA-4C5A-98FE-76673B29C9E3

P698

Q28600880-E53111D7-44CE-481E-84DB-69E4ECF6083F

P932

Q28600880-A5104FC9-87F3-49C0-AF75-3317E4E11D0D

P953

Q28600880-3F75E93F-FDA3-424B-BD32-3E5FE6DD3C8A

Q28600880-981EB909-7442-4E3E-9487-3BB48BA3033E

P3181

P356

P1433

P1476

Prolonged dual antiplatelet th ...... ected versus trial populations

@en

P2093

A Moayyeri

http://www.w3.org/2001/XMLSchema#string

A Timmis

http://www.w3.org/2001/XMLSchema#string

C Emmas

http://www.w3.org/2001/XMLSchema#string

D Stogiannis

http://www.w3.org/2001/XMLSchema#string

E Rapsomaniki

http://www.w3.org/2001/XMLSchema#string

H Hemingway

http://www.w3.org/2001/XMLSchema#string

L Pasea

http://www.w3.org/2001/XMLSchema#string

S C Chung

http://www.w3.org/2001/XMLSchema#string

P2860

Data resource profile: cardiovascular disease research using linked bespoke studies and electronic health records (CALIBER)

Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups

Completeness and diagnostic validity of recording acute myocardial infarction events in primary care, hospital care, disease registry, and national mortality records: cohort study

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

Completeness and usability of ethnicity data in UK-based primary care and hospital databases.

Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective.

Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people

A distribution-based method for assessing the differences between clinical trial target populations and patient populations in electronic health records.

Socioeconomic deprivation and the incidence of 12 cardiovascular diseases in 1.9 million women and men: implications for risk prediction and prevention.

Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure.

P304

i3163

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

568651

http://www.w3.org/2001/XMLSchema#string

P356

10.1136/BMJ.I3163

http://www.w3.org/2001/XMLSchema#string

P407

P478

353

http://www.w3.org/2001/XMLSchema#string

P50

Spiros C Denaxas

Anoop Dinesh Shah

Mar Pujades-Rodríguez

P5530

8971994

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1047331281

http://www.w3.org/2001/XMLSchema#string

P698

27334486

http://www.w3.org/2001/XMLSchema#string

P932

4916922

http://www.w3.org/2001/XMLSchema#string

P953